托西利祖马布治疗非传染性尿道炎:系统性审查
Haixing Cao1, Kaiyu Bian1, Cong Ma1
1Department of Ophthalmology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, People's Republic of China.
Journal of inflammation research
|September 26, 2025
概括
当标准疗法失败时,托西利祖马布 (TCZ) 显示出对治疗非传染性脑膜炎 (NIU) 的承诺. 这次审查发现TCZ改善了大多数耐火NIU患者的视力和控制炎症.
科学领域:
- 眼科医生 眼科 眼科
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
背景情况:
- 非传染性脑膜炎 (NIU) 会导致严重的眼部炎症和视力丧失.
- 现有的治疗方法,如皮质类固醇和免疫抑制剂,往往是不够的.
- 由于慢性症状和治疗挑战,NIU显著影响患者的生活质量.
研究的目的:
- 系统地审查托西利祖马布 (TCZ) 治疗NIU的疗效和安全性.
- 为了评估TCZ在耐火性NIU患者的有效性,该NIU对其他治疗无反应.
主要方法:
- 在PubMed,Web of Science和Embase的系统文献搜索到2025年5月1日.
- 包括病例报告和小型研究报告视力敏度和干预细节.
- 使用纽卡斯尔-太华尺度评估方法质量,使用JBI工具评估偏差风险.
主要成果:
- 该审查包括96名患者,其中贝塞特病和帕努韦炎是常见的.
- 大多数患者之前多次免疫抑制剂和生物药物失败.
- 在62.5%的患者中,TCZ改善了视力,在83.3%的患者中控制了炎症,在90.9%的患者中消除了黄斑.
- 总体而言,83.3%的患者对TCZ产生了良好的反应.
结论:
- 托西利祖马布 (TCZ) 是耐火性非传染性脑膜炎 (NIU) 的有效替代品.
- 在改善视觉结果和控制眼部炎症方面,TCZ显示出显著的潜力.
- 对TCZ在NIU的长期安全性和有效性的进一步研究是有必要的.
相关概念视频
Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...


